SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics announced positive Phase II trial data for its…

MiNK Therapeutics · PRESS-RELEASE filed Apr 17, 2026 at 15:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 17, 2026 at 15:00 ET

MiNK Therapeutics announced positive Phase II trial data for its agenT-797 cell therapy in combination with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer, showing a 77% disease control rate and improved survival with an induction strategy. Despite missing the primary endpoint of ORR, the durable responses and immune activation support further development. The data are being presented at AACR 2026.

  • Phase II trial (n=17) showed 77% disease control rate (DCR) in PD-1 refractory gastroesophageal cancer patients.
  • Induction strategy with agenT-797 led to median PFS of 6.9 months vs. 3.5 months (HR 0.19; p=0.015) and median OS of 9.5 vs. 5.2 months.
  • 43% of induction-treated patients were alive at 12 and 18 months, compared to 20% and 0% in non-induction cohort.
  • Trial did not meet primary endpoint of ORR, but durable disease control and survival are emphasized as key benefits.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access